Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia.

Anne-Cécile Gauchy; Maxime Hentzien; Alain Wynckel; Victoire De Marcellus; Cyrielle Rodier; Alain Delmer; Anne Quinquenel

doi:10.22541/au.158739918.81604679

loading page

Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia.

Anne-Cécile Gauchy,
Maxime Hentzien,
Alain Wynckel,
Victoire De Marcellus,
Cyrielle Rodier,
Alain Delmer,
Anne Quinquenel

Abstract

We report a case of refractory life-threatening warm autoimmune hemolytic anemia (wAIHA) associated with chronic myelomonocytic leukemia (CMML) for which all conventional treatments had failed. The use of eculizumab allowed controlling hemolysis and resulted in transfusion independence. These data support the use of eculizumab in refractory wAIHA.

14 Apr 2020Submitted to Clinical Case Reports

Show details

Hide details

20 Apr 2020Submission Checks Completed

20 Apr 2020Assigned to Editor

29 Apr 2020Reviewer(s) Assigned

10 Jun 2020Review(s) Completed, Editorial Evaluation Pending

10 Jun 2020Editorial Decision: Revise Minor

04 Jul 20201st Revision Received

04 Jul 2020Submission Checks Completed

04 Jul 2020Assigned to Editor

10 Jul 2020Review(s) Completed, Editorial Evaluation Pending

12 Jul 2020Reviewer(s) Assigned

21 Jul 2020Editorial Decision: Accept

Abstract

Peer review status:ACCEPTED